Table 1—

Patient characteristics

VariableItt analysispp analysis
MorningEveningMorningEvening
Patients n110998880
M:F n65:4549:5054:3440:40
Age yrs39 (19–75)38 (18–68)39 (19–75)36 (18–68)
Nonsmokers:/(Ex-)Smokers n61:4954:4549:3943:37
Pretreated:nonpretreated with ICS n41:6937:6231:5728:52
ICS pretreatment dose in BDP equivalents µg500 (50–1000)500 (200–500)500 (200–500)500 (200–500)
FEV1 % predicted77±977±1177±975±11
Reversibility % baseline23.5±1122.8±1124.5±1123.8±12
Morning PEF % predicted90±1887±2090±2086±8
  • Median (range)

  • Pretreatment was calculated as 500 µg beclomethasone dipropionate (BDP)=500 µg flunisolide=400 µg budesonide=250 µg fluticasone propionate, irrespective of type of device

  • It: intention-to-treat

  • pp: per-protocol

  • ICS: inhaled corticosterids

  • FEV1: Forced expiratory volume in one second

  • PEF: peak expiratory flow